The Gloria Soler Foundation supports a project by IrsiCaixa and the Northern Metropolitan Primary Care of the ICS to study the long-term immunity against COVID-19 in the elderly. In this way, the Glòria Soler Foundation continues its collaboration with IrsiCaixa, with whom it has previously worked on the study of the vaccine against HIV/AIDS.
The coexistence of various diseases and a compromised immune system makes older people more vulnerable to severe COVID-19. Being, therefore, a risk group, it is very important to dedicate efforts to analyze their level of protection against SARS-CoV-2, both after having passed the infection and after having been vaccinated. In this sense, the Glòria Soler Foundation supports a project of IrsiCaixa and the North Metropolitan Primary Care of the Catalan Institute of Health (ICS) that studies the degree of protection and the duration of the immune response in elderly people living in residences, after receiving the vaccine or passing the natural infection.
In addition, the study evaluates how the aging of the immune system affects the creation of an effective protective immune response. The results of this research will allow clinical decisions to be made, such as establishing a vaccination schedule based on the immune response.
As we age, our immune system deteriorates and it loses its ability to last for some functions. In this way, when fighting infections, like that of SARS-CoV-2, the immune response is each year less robust and more inefficient.
The CoronAVIS project takes various residences for the elderly as a field of study, since it is here that the COVID-19 pandemic has caused the most damage. To carry it out, 98 elderly people living in geriatric residences are monitored. The study consists of evaluating, over time, the quantity, quality and duration of their immune, humoral and cellular responses, generated from the Pfizer vaccine, in order to be able to compare them with the responses of 40 young people.
Finally, the study aims to associate the aging of the immune system with the ability of older people to respond to the vaccine. It is essential to control the immune response of this group and thus be able to adjust their vaccination schedule and guarantee the protection of this vulnerable population.
News on the IrsiCaixa website
Visit the news published by IrsiCaixa about the Glòria Soler Foundation’s collaboration with this studyLink